Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset

BACKGROUND: Tolvaptan is the only available disease-modifying treatment for autosomal dominant polycystic kidney disease (ADPKD). Prior to October 2020 access to tolvaptan in Australia was restricted by a controlled monitoring and distribution program called IMADJIN®. Focusing on hepatic safety, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Mark, Gois, Pedro Henrique Franca, Butcher, Belinda E., Ta, Michelle H. T., Van Wyk, Greg W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638092/
https://www.ncbi.nlm.nih.gov/pubmed/34856944
http://dx.doi.org/10.1186/s12882-021-02607-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638092/
https://www.ncbi.nlm.nih.gov/pubmed/34856944
http://dx.doi.org/10.1186/s12882-021-02607-4

Ejemplares similares